Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | PTPRC | P08575 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991531 | 0.92 | ALDH1A1 (0.62) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL5395231 | 0.87 | ALDH1A1 (0.61) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL16738656 | 0.87 | ELANE (0.61) | ALDH1A1KMT2ATDP1L3MBTL1SLC6A2 | |
| SCHEMBL3295418 | 0.86 | ALDH1A1 (0.59) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL25953192 | 0.86 | MMP8 (0.55) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL522510 | 0.85 | ALDH1A1 (0.62) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL15106055 | 0.84 | ALDH1A1 (0.58) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL991818 | 0.84 | ALDH1A1 (0.53) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL3296206 | 0.84 | ALDH1A1 (0.53) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL993585 | 0.84 | ALDH1A1 (0.53) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534453-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20240246939-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2024-07-25 | — | — | US | disclosed |
| CN-117956985-A | Inhibitors of glycogen synthase 1 (GYS 1) and methods of use thereof | 梅兹治疗公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-4308095-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| WO-2023173132-A1 | ANTI-GLP1R ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230104740-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2023-04-06 | — | — | US | disclosed |
| US-20230083012-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2023-03-16 | — | — | US | disclosed |
| EP-0662957-B1 | 1,4-DISUBSTITUTED PIPERAZINES USEFUL IN THE THERAPY OF THE ASTHMA AND OF THE INFLAMMATION OF THE RESPIRATORY TRACT | BOEHRINGER MANNHEIM ITALIA (IT) | 1997-11-05 | — | — | EP | disclosed |
| US-5607930-A | 1,4-disubstituted piperazines useful in the therapy of the asthma and of the inflammation of the respiratory tract | BOEHRINGER MANNHEIM ITALIA, S.P.A. (IT) | 1997-03-04 | — | — | US | disclosed |
| EP-0662957-A1 | 1,4-DISUBSTITUTED PIPERAZINES USEFUL IN THE THERAPY OF THE ASTHMA AND OF THE INFLAMMATION OF THE RESPIRATORY TRACT | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1995-07-19 | — | — | EP | disclosed |
| WO-1994007856-A1 | 1,4-DISUBSTITUTED PIPERAZINES USEFUL IN THE THERAPY OF THE ASTHMA AND OF THE INFLAMMATION OF THE RESPIRATORY TRACT | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1994-04-14 | — | — | WO | disclosed |
| EP-0121383-B1 | BIS-ESTERS OF DICARBOXYLIC ACIDS WITH AMOXICILLIN AND CERTAIN HYDROXYMETHYLPENICILLANATE 1,1-DIOXIDES | PFIZER INC. (US) | 1986-05-07 | — | — | EP | disclosed |
| EP-0083484-B1 | 1,1-ALKANEDIOL DICARBOXYLATE LINKED ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 1986-02-19 | — | — | EP | disclosed |
| EP-0121383-A1 | Bis-esters of dicarboxylic acids with amoxicillin and certain hydroxymethylpenicillanate 1,1-dioxides | PFIZER INC. (US) | 1984-10-10 | — | — | EP | disclosed |
| US-4462934-A | BACTERICIDES FROM PENICILLINS AND PENICILLINASE INHIBITORS | PFIZER INC. (US) | 1984-07-31 | — | — | US | disclosed |
| US-4457924-A | PENICILLINS, OXAPENICILLINS, BETA-LACTAMASE INHIBITORS | PFIZER, INC. (US) | 1984-07-03 | — | — | US | disclosed |
| EP-0083484-A1 | 1,1-Alkanediol dicarboxylate linked antibacterial agents | PFIZER INC. (US) | 1983-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | ALDH1A1 2458/4885KMT2A 3378/4885TDP1 357/4885 |
| US-20230104740-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | GYS2, GYS1, PYGL | ALDH1A1 2458/4885KMT2A 3378/4885TDP1 357/4885 |
| US-12534453-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS1, GYS2, GBA1 | ALDH1A1 2276/4885KMT2A 4082/4885TDP1 415/4885 |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | GLP1R, GIPR, GCGR | ALDH1A1 1481/4885KMT2A 1978/4885TDP1 3766/4885 |
| US-20230083012-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | ALDH1A1 1212/4885KMT2A 3329/4885TDP1 1612/4885 |
| US-20240246939-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | GYS2, GYS1, PYGL | ALDH1A1 2458/4885KMT2A 3378/4885TDP1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.